Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T38310 |
Luciferase-IN-1
|
Reactive Oxygen Species; Antibacterial; Antifungal | Immunology/Inflammation; Metabolism; Microbiology/Virology; NF-κB |
Luciferase-IN-1 是一种荧光素酶抑制剂,可用于研究细菌感染和真菌感染。 | |||
T9943 |
Firefly luciferase-IN-1
|
Others | Others |
Firefly luciferase-IN-1 是一种 2-亚苄基四氢萘酮衍生物,可在试剂盒中用作萤火虫荧光素酶抑制剂。 | |||
T78389 |
Coelenteramine 400a
Bisdeoxycoelenterazine,Coelenterazine 400a |
||
Coelenterazine 400a(Coelenterazine 400a),作为Coelenterazine的一个衍生物,它是海肾荧光素酶(RLuc)的底物。该化合物与RLuc结合后能够在395 nm发射蓝光。Coelenterazine 400a改变了亚甲基桥的硫和氧原子,导致RLuc的生物发光产生色变。它在提供更高的信号分辨率方面具有重要价值,适用于生物发光共振能量转移(BRET)的研究。 | |||
T13364 |
YAP/TAZ inhibitor-1
|
ROCK | Cell Cycle/Checkpoint; Cytoskeletal Signaling; Stem Cells |
YAP/TAZ inhibitor-1 is an inhibitor of YAP/TAZ (IC50 of <0.100 μΜ in firefly luciferase assay). | |||
T29336 |
2-Bromo-1-decanal
Decanal-1-14C, 2-bromo-, (R)-,2-Bromo(1-14C)-1-decanal |
||
2-Bromo-1-decanal was synthesized as an affinity labeling probe for the aliphatic aldehyde site of Vibrio harveyi luciferase. In the presence of excess amounts of this probe, the inactivation of bacterial luciferase occurred following apparent first order | |||
T69241 |
MEISi-1
|
||
MEISi-1 is a novel MEIS inhibitor (MEISi), significantly inhibiting MEIS-luciferase reporters in vitro and inducing murine (LSKCD34low cells) and human (CD34+, CD133+, and ALDHhi cells) HSC self-renewal ex vivo. | |||
T78413 |
ETZ
C3-CA-DTZ |
||
ETZ (C3-CA-DTZ) 是一种具潜力的荧光素酶前体,能在体内经非特异性酯酶活化,促进荧光素在脑部的传输。 | |||
T38223 |
N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide
|
||
N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide binds to the cannabinoid 1 (CB1) receptor with a Ki value of 365 nM in a radioligand binding assay using rat brain homogenate. It has an EC50 value of 698 nM for the peroxisome proliferator-activated receptor α (PPARα) in a luciferase reporter assay and, in rats, it decreases food intake. It does not inhibit fatty acid amide hydrolase (FAAH). | |||
T78419 |
lucPpy-IN-1
|
||
LucPpy-IN-1(化合物9)是一种针对ATP依赖性萤火虫荧光素酶(lucPpy)的抑制剂,其IC50为4.0 μM,适用于进行靶点药物敏感性研究。 | |||
T37092 |
20-HEPE
|
||
20-HEPE is a metabolite of eicosapentaenoic acid that is formed via ω-oxidation of EPA by cytochrome P450 (CYP) ω-oxidases, including human CYP4F3B. It activates peroxisome proliferator-activated receptor α (PPARα) in COS-7 cells expressing a luciferase reporter when used at a concentration of 10 μM. 20-HEPE also activates murine transient receptor potential vanilloid receptor 1 (mTRPV1) in vitro but lacks antinociceptive activity in rats. | |||
T70138 | AZ0108 | ||
AZ0108 is an orally bioavailable, potent PARP1,2,6 inhibitor that potently inhibits centrosome clustering and is suitable for in vivo efficacy and tolerability studies. AZ0108 has been utilized as in vitro tools and in vivo probes to investigate the biological consequences of inhibiting centrosome clustering through PARP enzymes. AZ0108 is more selective in its enzyme inhibition profile and effects on cellular pathways and phenotypes. Specifically, AZ0108 inhibits PARPs 1, 2, and 6 with approxi... | |||
T81342 |
pyCTZ hydrochloride
Pyridyl CTZ hydrochloride |
||
pyCTZ hydrochloride(Pyridyl CTZ),作为一种CTZ(腔肠素)类似物,是LumiLuc荧光素酶的ATP非依赖性吡啶基底物。在荧光素酶的作用下,pyCTZ hydrochloride能发出强烈的蓝色生物发光,适用于基于水母发光蛋白的钙感测。 | |||
T72056 |
KYN-101
|
||
KYN-101是一种高效、选择性的芳香烃受体(AHR)合成拮抗剂,在人HepG2 DRE 荧光素酶报告基因检测中IC50为22 nM,在小鼠Hepa1 Cyp-luc 检测中IC50为23 nM。KYN-101逆转IDO/TDO 介导的肿瘤进展,提高PD-1阻断B16 IDO 荷瘤小鼠和表达内源性高水平IDO 的CT26结直肠癌模型的疗效。 | |||
T35800 |
MD001
|
||
MD001 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ.1 It binds to PPARα and PPARγ (Kds = 9.55 and 0.14 μM, respectively) but does not bind to PPARβ/δ at concentrations up to 500 μM. It increases transcriptional activity of PPARα and PPARγ in a cell-based luciferase reporter assay when used at a concentration of 10 μM. MD001 (10 μM) increases expression of PPARα, PPARγ, and retinoid X receptor (RXR), as well as PPARα and PPARγ target genes, in HepG2 cells. It... | |||
T36574 |
GW841819X
GW841819X |
||
GW841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomains. GW841819X was a single enantiomer but of undefined chirality at the 4-position of the benzodiazepine ring3. GW841819X and JQ1 were recently discovered that bind to the acetyl-lysine binding pocket of BET bromodomains with Kd ranges from 50 to 370 nM [1]. GW841819X bounded to both the individual BD1 and BD2 domains with affinities of 46 and 52.5 nM, respectively. GW841819X-Brd3 interaction was estimated to be around 70... |